Superior efficacy and comparable safety was seen with DFD-29 in patients with rosacea when compared with the current first-line systemic.
MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and ...
ROCKVILLE, MD – There is a need for the scientific community to explore the use of additional strength biowaivers for modified release (MR) drugs given the increasing market demand for these “patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results